title: Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease.
abstract: In a study recently published in Science, Magnon et al. show that both the sympathetic and parasympathetic components of the autonomic nervous system play an integral part in the development and dissemination of prostate cancer (PCa). Inhibition of the sympathetic nervous system (SNS) and disruption of the adrenergic receptors, specifically Ardβ 2, resulted in the prevention of primary PCa tumor development in mice. The authors found that inhibition of the SNS is only successful in preventing murine tumor development if completed early enough, and the parasympathetic nervous system (PNS) predominates in later stages of PCa. Inhibition of the PNS by way of the cholinergic receptor, muscarinic 1 (Chrm1), caused mice to develop less metastases to the pelvic lymph nodes, intestines, and bones. A PCa progression scheme has been outlined where initial tumor engraftment is controlled by the SNS but then becomes less prominent than the PNS, which promotes metastasis. The investigators showed the dependence of the autonomic nervous system on development of PCa and present opportunities for prevention; further studies are needed to confirm these results in humans.
authors.affiliation: Molecular Pharmacology Section; Medical Oncology Branch; National Cancer Institute; Bethesda, MD USA.
authors.forename: Elena V
authors.initials: EV
authors.lastname: Fernández
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Price
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000818:Animals; D001341:Autonomic Nervous System / Q000254:growth & development*; D006801:Humans; D008297:Male; D055495:Neurogenesis; D011467:Prostate / Q000294:innervation* / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology*
keywords: autonomic nervous system; metastasis; primary tumor development; prostate cancer; stromal cholinergic muscarinic receptor type 1; β2- β3- adrenergic receptors
references.citation: Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1087-92
references.pmid: 9719119
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2635-44
references.pmid: 21632503
references.citation: Hum Pathol. 2001 Aug;32(8):828-33
references.pmid: 11521227
references.citation: Eur Urol. 2011 Oct;60(4):691-8
references.pmid: 21705134
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2645-52
references.pmid: 21632501
references.citation: J Urol. 1989 Sep;142(3):763-8
references.pmid: 2769857
references.citation: Prostate. 2013 Feb 15;73(3):250-60
references.pmid: 22821802
references.citation: Science. 2013 Jul 12;341(6142):1236361
references.pmid: 23846904
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7593-603
references.pmid: 19047084
references.citation: Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8
references.pmid: 16613526